Searchable abstracts of presentations at key conferences in endocrinology

ea0029p80 | Adrenal cortex | ICEECE2012

RRM1 Gene expression affects metabolization and activity of mitotane in adrenocortical cancer cell lines.

Germano A. , Rapa I. , De Francia S. , Volante M. , Laino F. , Duregon E. , Berruti A. , Papotti M. , Terzolo M.

Background: Mitotane (o,p’DDD) is the reference therapy for adrenocortical carcinoma (ACC) and should undergo metabolization in o,p’DDE and o,p’DDA to exert its anti-proliferative activity. We have previously shown that there is a link between RRM1 gene expression and o,p’DDD activity in an adjuvant setting. Aim of this study was to assess whether RRM1 gene expression is correlated to the bioavailability and cytotoxic activity of o,p’DDD and its metabo...

ea0029oc7.3 | Adrenal Clinical | ICEECE2012

Ribonucleotide reductase large subunit (RRM1) gene expression predicts efficacy of adjuvant mitotane in adrenocortical cancer

Volante M. , Terzolo M. , Fassnacht M. , Rapa I. , Germano A. , Sbiera S. , Daffara F. , Sperone P. , Scagliotti G. , Allolio B. , Papotti M. , Berruti A.

Purpose: Mitotane is the reference systemic therapy for adrenocortical carcinoma (ACC), but its mechanism of action and possible predictors of treatment response remain poorly defined. Our aim was to evaluate the gene expression of ribonucleotide reductase large subunit 1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) in ACC as potential biomarkers for clinical outcome and response to mitotane.Experimental design: Forty-five and 47 tiss...